The short version of CAS Registry Number fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
=== Germany === In Germany, postgraduate medical training leading to specialization is generally referred to as Facharztweiterbildung. After obtaining the required authorization to practise medicine, physicians can apply for positions in approved hospitals and training institutions and complete specialist training while working under supervision. For international medical graduates, the pathway typically involves recognition of their medical qualifications, fulfilment of language requirements, and the applicable medical licensing process.
==== Factors that affect the typical range ==== The effect or race and gender on value of BNP and its utility in that context has been studied extensively. BNP is cleared by binding to natriuretic peptide receptors (NPRs) and neutral endopeptidase (NEP). Less than 5% of BNP is cleared renally. NT-proBNP is the inactive molecule resulting from cleavage of the prohormone Pro-BNP and is reliant solely on the kidney for excretion. The "Achilles' heel" of the NT-proBNP biomarker is the overlap in kidney disease in the heart failure patient population: kidney disease patients remove NT-proBNP slower than usual, making an elevated value hard to interpret. When interpreting an elevated BNP level, values may be elevated due to factors other than heart failure. Lower levels are often seen in obese patients. Higher levels are seen in those with renal disease, in the absence of heart failure.
== Interactions == If diazepam is administered concomitantly with other drugs, it is recommended that attention be paid to the possible pharmacological interactions. Particular care is taken with drugs that potentiate the effects of diazepam, such as barbiturates, phenothiazines, opioids, and antidepressants. Diazepam does not increase or decrease hepatic enzyme activity and does not alter the metabolism of other compounds. No evidence has suggested that diazepam alters its metabolism with chronic administration. Agents with an effect on hepatic cytochrome P450 pathways or conjugation can alter the rate of diazepam metabolism. These interactions would be expected to be most significant with long-term diazepam therapy, and their clinical significance is variable.
== Medical uses == In the United States, gemtuzumab ozogamicin is indicated for newly diagnosed CD33-positive acute myeloid leukemia (AML) for adults and children one month and older and for the treatment of relapsed or refractory CD33-positive AML in adults and children two years and older.
== Development == In 1953, English biophysicist Francis Crick and American biologist James Watson, working together at the Cavendish Laboratory of the University of Cambridge, worked out the correct description of the structure of DNA, one of the major genetic materials. In their follow-up paper the same year, they introduced the concept of genetic information alongside the notion that DNA and protein cloud be related. By 1954, it was becoming to be understood that DNA, RNA (only messenger RNA was understood at the time, but only as a vague nucleic acid, and identified as such only in 1960) and proteins were related as components of the same genetic information pathway. However, the structure of RNA and details of how these biological molecules related and interact with each other were still a mystery, especially on how proteins could be synthesised from nucleic acids. Watson called this problem "the mysteries of life" in his letter to Crick. Watson and Alexander Rich discussed in the PNAS, saying, "We shall not be able to check a structural relationship between RNA and protein synthesis or between RNA and DNA until we know the structure of RNA." Evidences had been accumulating since the 1940s that protein synthesis occurs simultaneously with increased level of RNA in the cytoplasm. The relationship between DNA and RNA for protein synthesis was first hypothesised by French biologist André Boivin and Roger Vendrely in 1947.
Sources: en.wikipedia.org
The Ilyushin Il-86 (Russian: Илью́шин Ил-86; NATO reporting name: Camber) is a retired short- to medium-range wide-body jet airliner that served as the USSR's first wide-bodied aircraft. Designed and tested by the Ilyushin design bureau in the 1970s, it was certified by the Soviet aircraft industry, manufactured and marketed by the USSR. Developed during the rule of Leonid Brezhnev, the Il-86 was marked by the economic and technological stagnation of the era: it used engines more typical of the late 1960s, spent a decade in development, and failed to enter service in time for the 1980 Summer Olympics in Moscow, as was originally intended. The type was used by Aeroflot and successor post-Soviet airlines; only three of the total 106 constructed were exported. At the beginning of 2012, only four Il-86s remained in service, all with the Russian Air Force. By the end of 2020 the number in active service was reduced to three.
=== Functionally characterized genes involved in AGP glycosylation === Bioinformatics analysis using mammalian β-1,3-galactosyltransferase (GalT) sequences as templates suggested involvement of the Carbohydrate-Active enZYmes (CAZy) glycosyltransferase (GT) 31 family in the synthesis of the galactan chains of the AG backbone. Members of the GT31 family have been grouped into 11 clades, with four clades being plant-specific: Clades 1, 7, 10, and 11. Clades 1 and 11 domains and motifs are not well-defined; while Clades 7 and 10 have domain similarities with proteins of known GalT function in mammalian systems. Clade 7 proteins contain both GalT and galectin domains, while Clade 10 proteins contain a GalT-specific domain. The galectin domain is proposed to allow the GalT to bind to the first Gal residue on the polypeptide backbone of AGPs; thus, determining the position of subsequent Gal residues on the protein backbone, similar to the activity of human galectin domain-containing proteins. Eight enzymes belonging to the GT31 family demonstrated the ability to place the first Gal residue onto Hyp residues in AGP core proteins. These enzymes are named GALT2, GALT3, GALT4, GALT5, GALT6, which are Clade 7 members, and HPGT1, HPGT2, and HPGT3, which are Clade 10 members. Preliminary enzyme substrate specificity studies demonstrated that another GT31 Clade 10 enzyme, At1g77810, had β-1,3-GalT activity. A GT31 Clade 10 gene, KNS4/UPEX1, encodes a β-1,3-GalT capable of synthesizing β-1,3-Gal linkages found in type II AGs present in AGPs and/or pectic rhamnogalacturonan I (RG-I).
PFAS are used in Class B firefighting foams due to their hydrophobic and lipophobic properties, as well as the stability of the chemicals when exposed to high heat. Though studies have been frequently limited by underpowered study designs, research indicates firefighters have higher blood levels of PFOS and PFHxS than the general population. PFAS exposure is prevalent among firefighters not only due to its use in emergencies but also because it is used in personal protective equipment. In support of these findings, states like Washington and Colorado have moved to restrict and penalize the use of Class B firefighting foam for firefighter training and testing. The September 11 attacks and resulting fires caused the release of toxic chemicals used in materials such as stain-resistant coatings. First responders to this incident were exposed to PFOA, PFNA, and PFHxS through inhalation of dust and smoke released during and after the collapse of the World Trade Center. First responders who were working at or near ground zero were assessed for respiratory and other health effects from exposure to emissions at the World Trade Center. Early clinical testing showed a high prevalence of respiratory health effects. Early symptoms of exposure often presented with persistent coughing and wheezing. PFOA and PFHxS levels were present in both smoke and dust exposure, but first responders exposed to smoke had higher concentrations of PFOA and PFHxS than those exposed to dust.
=== Bond specificity === Bond specificity, unlike group specificity, recognizes particular chemical bond types. This differs from group specificity, as it is not reliant on the presence of particular functional groups in order to catalyze a particular reaction, but rather a certain bond type (for example, a peptide bond).
=== Early life and education === William H. Stein was born on June 25, 1911 in New York City into a Jewish family. His father, Fred M. Stein, was a businessman who retired early to support local New York health organizations. His mother, Beatrice Borg Stein, was a children's rights activist who developed afterschool activities. Staunch advocates for the welfare of society, Stein's parents fostered his interests in the life sciences from a young age. As a child, Stein attended the recently established "progressive" Lincoln School which was sponsored by the Teachers College of Columbia University; there, he was able to explore the natural sciences through field trips and science projects. At the age of sixteen, Stein was transferred to the Phillips Exeter Academy in New England to prepare for higher education. In 1936, during his graduate studies at Columbia University, William H. Stein married Phoebe Hockstader. They had three sons together: William H. Stein, Jr., David F. Stein, and Robert J. Stein. Stein lived with his family in New York the rest of his life—mainly in Manhattan and briefly in Scarsdale, New York.
Sources: en.wikipedia.org
=== South America === The South American continent contains some of the oldest mummies in the world, both deliberate and accidental. The bodies were preserved by the best agent for mummification: the environment. The Pacific coastal desert in Peru and Chile is one of the driest areas in the world and the dryness facilitated mummification. Rather than developing elaborate processes such as later-dynasty ancient Egyptians, the early South Americans often left their dead in naturally dry or frozen areas, though some did perform surgical preparation when mummification was intentional. Some of the reasons for intentional mummification in South America include memorialization, immortalization, and religious offerings. A large number of mummified bodies have been found in pre-Columbian cemeteries scattered around Peru. The bodies had often been wrapped for burial in finely-woven textiles.
Major production sites include Sulawesi, Indonesia, the Sudbury region of Canada, New Caledonia in the Pacific, Western Australia, and Norilsk, Russia. Nickel is one of four elements (the others are iron, cobalt, and gadolinium) that are ferromagnetic at about room temperature. Alnico permanent magnets based partly on nickel are of intermediate strength between iron-based permanent magnets and rare-earth magnets. The metal is used chiefly in alloys and corrosion-resistant plating. About 68% of world production is used in stainless steel. A further 10% is used for nickel-based and copper-based alloys, 9% for plating, 7% for alloy steels, 3% in foundries, and 4% in other applications such as in rechargeable batteries, including those in electric vehicles (EVs). Nickel is widely used in coins, though nickel-plated objects sometimes provoke nickel allergy. As a compound, nickel has a number of niche chemical manufacturing uses, such as a catalyst for hydrogenation, cathodes for rechargeable batteries, pigments and metal surface treatments. Nickel is an essential nutrient for some microorganisms and plants that have enzymes with nickel as an active site.
By the time of nominations closing in April 2026, however, Galloway was no longer standing as a constituency candidate in Glasgow Southside, though remained on the regional ballot. He was unsuccessful, as were all other Workers Party candidates in the election. On 27 September 2025, while returning from Moscow through Abu Dhabi, George Galloway and his wife Putri Gayatri Pertiwi were stopped and questioned at Gatwick Airport by the Metropolitan Police's Counter Terrorism Command under the Counter-Terrorism and Border Security Act 2019 and questioned on his opinions of Russia, and China. His party condemned this as "politically motivated intimidation". The Metropolitan Police said "Neither of them were arrested and they were allowed on their way". Following the arrest Galloway entered a "self-imposed exile" in Russia. On the 4 September 2026, the Bank of Scotland closed Galloway's account prompting him to condemn the bank on X, saying "I will not stand by while you use your usurious power to wreck my family life." on the matter. In preparation for the 2026 Greater Manchester mayoral by-election, Galloway announced his candidacy on 19 June 2026. However, when nominations were released on 6 July, he was not listed as a candidate and was not included on the ballot. On the 14 September 2026 George Galloway announced his intention to stand in the 2026 Holborn and St. Pancras by-election on his podcast, MOATS.
According to the Nigerian constitution, all minerals, gas, and oil the country possesses are legally the property of the Nigerian Federal Government. The revenue gained by the NNPC accounts for 76% of federal government revenue and 40% of the entire country's GDP. As of 2000, oil and gas exports account for 98% of Nigerian export earnings.
== Reception == Justin Chang gave the film a positive review in Variety, describing it as "a precocious if rather precious debut feature for writer-director Jennifer Phang", praising the film's computer generated effects and the representation of Tim and Pam's relationship through Aasulv Wolf Austad's cinematography, comparing it to the works of Apichatpong Weerasethakul. The Hollywood Reporter was similarly positive, criticizing the film as suffering from budget restraints, but praising Phang's depiction of the two households for capturing dark humor as well as "real pain and anguish", in addition to praising Alexander Agate's performance.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.